
This communique outlines key discussion outcomes on the potential neural tube defect (NTD) safety signal in women taking dolutegravir (DTG) at conception and a joint position on behalf of women for access to optimal HIV treatment and prevention.
A framework to support new product introduction in national health systems
This communique outlines key discussion outcomes on the potential neural tube defect (NTD) safety signal in women taking dolutegravir (DTG) at conception and a joint position on behalf of women for access to optimal HIV treatment and prevention.